Sleep Apnea Pill Faces a February Decision After Regulators Questioned Whether Its Main Result Is Meaningful
AD109 cut breathing interruptions 44% in a 646 person trial. The FDA set a February 28 decision date and has questioned the primary endpoint.
Medical Daily ·